Citations

Clear

6273 citation(s) found for "To, Andrew".

Selective restoration of calcium coupling to muscarinic M3 receptors in contractile cultured airway myocytes
Mitchell, Richard W., Solway, Julian , Wylam, Mark E. , Halayko, Andrew J. , Kahraman, Sibel

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | December 24, 2017 | Volume: 278 | Issue: 5 | Pages: L1091-L1100

10.1152/ajplung.2000.278.5.l1091 | PMID 10781442 Get It

We previously demonstrated that after several days of serum deprivation about one-sixth of confluent cultured canine tracheal myocytes acquire an elongated, structurally and functionally contractile phenotype. These myocytes demonstrated significant shortening on ACh exposure. To evaluate the mechanism by which these myocytes acquire responsiveness to ACh, we assessed receptor-Ca2+ coupling using fura 2-AM fluorescence imaging and muscarinic receptor expression using Western analysis. Cells were grown to confluence in 10% fetal bovine serum and then maintained for 7–13 days in serum-free medium. A fraction of serum-deprived cells exhibited reproducible intracellular Ca2+ mobilization in response to ACh that was uniformly absent from airway myocytes before serum deprivation. The Ca2+ response to 10− 4 M ACh was ablated by inositol 1,4,5-trisphosphate (IP3) receptor blockade using 10− 6 M xestospongin C but not by removal of extracellular Ca2+. Also, 10− 7 M atropine or 10− 7 M 4-diphenylacetoxy- N-methylpiperidine completely blocked the response to ACh, but intracellular Ca2+ mobilization was not ablated by 10− 6 M pirenzepine or 10− 6 M methoctramine. In contrast, 10− 5 M bradykinin (BK) was without effect in these ACh-responsive myocytes. Interestingly, myocytes that did not respond to ACh demonstrated robust increases in intracellular Ca2+ on exposure to 10− 5 M BK that were blocked by removal of extracellular Ca2+ and were only modestly affected by IP3 receptor blockade. Serum deprivation increased the abundance of M3 receptor protein and of BK2 receptor protein by two- to threefold in whole cell lysates within 2 days of serum deprivation, whereas M2receptor protein fell by >75%. An increase in M3receptor abundance and restoration of M3 receptor-mediated Ca2+ mobilization occur concomitant with reacquisition of a contractile phenotype during prolonged serum deprivation. These data demonstrate plasticity in muscarinic surface receptor expression and function in a subpopulation of airway myocytes that show mutually exclusive physiological and pharmacological diversity with other cells in the same culture.
Stretch induces cytokine release by alveolar epithelial cells in vitro
Vlahakis, Nicholas E., Hubmayr, Rolf D., Schroeder, Mark A. , Limper, Andrew H.

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | December 23, 2017 | Volume: 277 | Issue: 1 | Pages: L167-L173

10.1152/ajplung.1999.277.1.l167 | PMID 10409244 Get It

Mechanical ventilation can injure the lung, causing edema and alveolar inflammation. Interleukin-8 (IL-8) plays an important role in this inflammatory response. We postulated that cyclic cell stretch upregulates the production and release of IL-8 by human alveolar epithelium in the absence of structural cell damage or paracrine stimulation. To test this hypothesis, alveolar epithelial cells (A549 cells) were cultured on a deformable silicoelastic membrane. When stretched by 30% for up to 48 h, the cells released 49 ± 34% more IL-8 ( P < 0.001) than static controls. Smaller deformations (20% stretch) produced no consistent increase in IL-8. Stretch of 4 h duration increased IL-8 gene transcription fourfold above baseline. Stretch had no effect on cell proliferation, cell viability as assessed by51Cr release assay, or the release of granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-α. We conclude that deformation per se can trigger inflammatory signaling and that alveolar epithelial cells may be active participants in the alveolitis associated with ventilator-induced lung injury.
Characterization of a mitogen-activated protein kinase fromPneumocystis carinii
Thomas, Charles F., Leof, Edward B. , Kottom, Theodore J. , Limper, Andrew H.

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | December 23, 2017 | Volume: 275 | Issue: 1 | Pages: L193-L199

10.1152/ajplung.1998.275.1.l193 | PMID 9688951 Get It

The pathogenic fungus Pneumocystis carinii causes severe pneumonia in patients with impaired immunity, particularly patients with acquired immunodeficiency syndrome. The life cycle of P. carinii is poorly understood, and the inability to continuously culture P. carinii is a major limitation in understanding its cell biology. In fungi homologous to P. carinii, pheromone mating factors signal through a mitogen-activated protein kinase (MAPK) signal transduction cascade, resulting in mitotic cell cycle arrest and entry into a pathway of conjugation, cellular differentiation, and proliferation. Using degenerate PCR and library screening, we have identified a MAPK cDNA in P. carinii that is highly homologous to fungal MAPKs involved in the pheromone mating signal transduction cascade, and we demonstrate MAPK activity in P. carinii lysates with a specific antiserum derived from the translated P. carinii MAPK cDNA sequence.
Pneumocystis cariniiinduces ICAM-1 expression in lung epithelial cells through a TNF-α-mediated mechanism
Yu, Mariette L., Limper, Andrew H.

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | December 23, 2017 | Volume: 273 | Issue: 6 | Pages: L1103-L1111

10.1152/ajplung.1997.273.6.l1103 | PMID 9435563 Get It

Inflammatory cell recruitment contributes to respiratory impairment during Pneumocystis carinii pneumonia. We evaluated expression of intercellular adhesion molecule-1 (ICAM-1), a key participant in leukocyte accumulation, in rats with P. carinii pneumonia. Immunostaining for ICAM-1 was most marked on bronchiolar epithelium but was also evident on type II pneumocytes, endothelium, and macrophages. Lung from normal and dexamethasone-treated uninfected animals exhibited markedly less ICAM-1. We hypothesized that P. carinii promoted ICAM-1 expression in epithelium through tumor necrosis factor-α (TNF-α) release from macrophages or that P. carinii directly stimulated ICAM-1 expression. Alveolar macrophages were incubated with P. carinii, and the medium was added to A549 epithelial cells. Treatment of macrophages with P. carinii enhanced A549 ICAM-1, which was inhibited with antibody to TNF-α. To determine whether P. carinii alone also stimulated ICAM-1, A549 cells were cultured with P. carinii, also augmenting ICAM-1. Of note, A549 ICAM-1 expression from P. carinii alone was less than with P. carinii-exposed macrophages. Thus ICAM-1 is enhanced in lung epithelium during P. carinii infection, in part, through TNF-α-mediated mechanisms.
Clinical utility of gastric emptying scintigraphy: Patient and physician perspectives
Tseng, Andrew S. , DiBaise, John K. , Tseng, A S , Crowell, Michael D.

Mayo Clinic

Neurogastroenterology & Motility | December 21, 2017 | Volume: 30 | Issue: 5 | Pages: No page available

10.1111/nmo.13279 | PMID 29266606 Get It

AbstractBackgroundThe use of gastric emptying scintigraphy (GES) in the evaluation of patients with dyspeptic symptoms is controversial. Our aim was to investigate objective and subjective parameters of clinical utility of GES from the perspectives of both the patient and the ordering physician.MethodsSocio‐demographic features, healthcare resource utilization, gastroparetic symptoms and quality of life (QoL) were obtained from consecutive patients referred for GES immediately prior to GES and again 4 months later. The ordering physician received a brief survey 2 weeks after the GES regarding their perceptions on whether the test provided them with clinically useful information.Key ResultsOne hundred and seventy‐two (mean age ± SD 52.0 ± 17.9; 78% female) of 266 patients enrolled completed both the baseline and follow‐up questionnaires and comprised our study population. At baseline, patients with abnormal GES had significantly higher gastroparesis symptom scores and reduced QoL. At the 4‐month follow‐up, an improvement in symptoms and QoL was seen, but the degree of improvement was not significantly different between those with a normal or abnormal GES. One hundred and ninety‐seven ordering physicians completed the survey and perceived that GES, particularly when abnormal, provided new information (91%) and resulted in a change in diagnosis (58%) and management (60%).Conclusions & InferencesAlthough patients with an abnormal GES generally had worse symptoms and lower QoL, the results of GES did not help to identify those with improved or worsened symptoms or QoL at follow‐up. Nevertheless, the ordering physicians generally felt that the results of GES were helpful in managing these patients.
Both HIV-Infected and Uninfected Cells Express TRAILshort, Which Confers TRAIL Resistance upon Bystander Cells within the Microenvironment
Nie, Zilin , Aboulnasr, Fatma, Natesampillai, Sekar, Burke, Stephen , Krogman, Ashton , Bren, Gary D., Chung, Thomas D.Y. , Anderson, J. , Smart, Michele, Katzmann, David J. , Rajagopalan, Govindarajan, Badley, Andrew D. , Burke, Stephen P , Anderson, Jeff R , Smart, Michele K, Cummins, Nathan W , Badley, Andrew D , Cummins, Nathan W.

Mayo Clinic

The Journal of Immunology | December 20, 2017 | Volume: 200 | Issue: 3 | Pages: 1110-1123

10.4049/jimmunol.1701113 | PMID 29263214 Get It

Abstract TNF-related apoptosis-inducing ligand (TRAIL) was initially described to induce apoptosis of tumor cells and/or virally infected cells, although sparing normal cells, and has been implicated in the pathogenesis of HIV disease. We previously identified TRAILshort, a TRAIL splice variant, in HIV-infected patients and characterized it as being a dominant negative ligand to subvert TRAIL-mediated killing. Herein, using single-cell genomics we demonstrate that TRAILshort is produced by HIV-infected cells, as well as by uninfected bystander cells, and that the dominant stimulus which induces TRAILshort production are type I IFNs and TLR7, TLR8, and TLR9 agonists. TRAILshort has a short t1/2 by virtue of containing a PEST domain, which targets the protein toward the ubiquitin proteasome pathway for degradation. Further we show that TRAILshort binds preferentially to TRAIL receptors 1 and 2 with significantly reduced interaction with the decoy TRAIL receptors 3 and 4. Recombinant TRAILshort is sufficient to protect cells against TRAIL-induced killing, whereas immunodepletion of TRAILshort with a specific Ab restores TRAIL sensitivity. Importantly we show that TRAILshort is shed in microvesicles into the cellular microenvironment and therefore confers TRAIL resistance not only on the cell which produces it, but also upon neighboring bystander cells. These results establish a novel paradigm for understanding and overcoming TRAIL resistance, in particular how HIV-infected cells escape immune elimination by the TRAIL:TRAILshort receptor axis.
Eosinophils promote inducible NOS–mediated lung allograft acceptance
Onyema, Oscar Okwudiri , Guo, Yizhan , Stoler, Mark H. , Lau, Christine L. , Li, Kang , Nazaroff, Christopher D. , Wang, Xingan , Kreisel, Daniel , Lee, James J. , Jacobsen, Elizabeth A. , Krupnick, Alexander S. , Nazaroff, Christopher Daniel, Jacobsen, Elizabeth A , Wang, Qing, Li, Wenjun , Gelman, Andrew E

Mayo Clinic

JCI Insight | December 20, 2017 | Volume: 2 | Issue: 24 | Pages: No page available

10.1172/jci.insight.96455 | PMID 29263310 Get It

Lungs allografts have worse long-term survival compared with other organ transplants. This is most likely due to their unique immunoregulation that may not respond to traditional immunosuppression. For example, local NO generation by inducible NOS (iNOS) is critical for lung allograft acceptance but associates with rejection of other solid organs. The source of NO in accepting lung allografts remains unknown. Here, we report that, unlike the case for other pulmonary processes in which myeloid cells control NO generation, recipient-derived eosinophils play a critical and nonredundant role in iNOS-mediated lung allograft acceptance. Depletion of eosinophils reduces NO levels to that of recipients with global deletion of iNOS and leads to a costimulatory blockade–resistant form of rejection. Furthermore, NO production by eosinophils depends on Th1 polarization by inflammatory mediators, such as IFN-γ and TNF-α. Neutralization of such mediators abrogates eosinophil suppressive capacity. Our data point to what we believe to be a unique and previously unrecognized role of eosinophil polarization in mediating allograft tolerance and put into perspective the use of high-dose eosinophil-ablating corticosteroids after lung transplantation.
Real‐world incidence of efficacy and safety outcomes in patients on direct oral anticoagulants with left ventricular systolic dysfunction at a tertiary referral center
Tseng, Andrew S. , Shen, Win‐Kuang , McBane, Robert D. , Mankad, Sunil , Esser, Heidi, Vucicevic, D., Shamoun, Fadi , Shamoun, Fadi E., Tseng, A S , McBane, Robert , Schleifer, J. William

Mayo Clinic

Clinical Cardiology | December 16, 2017 | Volume: 40 | Issue: 12 | Pages: 1328-1332

10.1002/clc.22833 | PMID 29247519 Get It

BackgroundPatients with heart failure (HF) have increased risk for thromboembolic events. Real‐world incidences of efficacy and safety outcomes of direct oral anticoagulants (DOACs) in patients with left ventricular systolic dysfunction (LVSD) are of growing clinical interest.HypothesisReal‐world efficacy and safety outcomes of DOACs in patients with LVSD will be similar to those of LVSD or HF subgroups in the RE‐LY, ROCKET‐AF, and ARISTOTLE trials.MethodsWe performed a retrospective review of adult patients with LVSD (left ventricular ejection fraction ≤40%) on DOAC therapy between 2010 and 2016. Incidences of safety and efficacy outcomes of anticoagulation with DOACs were extracted from primary and secondary hospital discharge diagnoses.ResultsDOACs were prescribed to 287 patients with LVSD over a mean follow‐up of 313.3 ± 52.3 days. Many patients had moderate and severe chronic kidney disease (28.9% and 10.1%, respectively) and indications for anticoagulation therapy other than atrial fibrillation (19.9%). For efficacy outcomes, the calculated incidence rates of ischemic stroke and systemic embolism were 1.2 (95% confidence interval [CI]: 0.25‐3.56) and 0.81 (95% CI: 0.10‐2.94) events per 100 person‐years, respectively. For the safety outcomes, incidence rates of GI bleeding and intracranial hemorrhage were 2.4 (95% CI: 0.8‐5.3) and 0.41 (95% CI: 0.1‐2.2) events per 100 patient‐years, respectively.ConclusionsOur findings are largely compatible with the results of LVSD or HF subgroups in RE‐LY, ROCKET‐AF, and ARISTOTLE trials and add to increasing confidence that DOACs can be safely used for stroke and systemic embolism prevention in patients with LVSD.
Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting
Walsh, Ryan R., Krismer, Florian , Galpern, Wendy R., Wenning, Gregor K. , Low, Phillip A. , Halliday, Glenda M. , Holton, Janice L. , Quinn, Niall , Rascol, Olivier , Shaw, Leslie M. , Eidelberg, David , Bower, Pam, Abler, Victor, Biedenharn, Judy, Bitan, Gal , Brundin, Patrik , Fernandez, Hubert, Fortier, Philip, Gasser, Thomas , Hewitt, Alice, Höglinger, Günter U. , Huentelman, Matt , Jensen, Poul Henning , Jeromin, Andreas, Kang, Un Jung , Kaufmann, Horacio , Kellerman, Lawrence R., Khurana, Vikram , Klockgether, Thomas , Kim, Woojin S. , Langer, Carol B., Masliah, Eliezer , Meissner, Wassilios G. , Ostrowitzki, Susanne, Piantadosi, Steven , Roemer, Cyndi, Schenk, Dale, Schlossmacher, Michael G. , Seppi, Klaus , Shih, Lily, Siderowf, Andrew , Stebbins, Glenn T. , Stefanova, Nadia , Sutton, Sharon Egretta, Zhang, Jing , Halliday, Glenda , Koroshetz, Walter J. , Holton, Janice, Quinn, Niall P, Brooks, David J. , Hewitt, Art, Huentelman, Matt J, Jensen, Poul H, Kellerman, Lawrence, Kim, Woojin Scott, Langer, Carol, LeWitt, Peter, Meissner, Wassilios, Melki, Ronald, Poewe, Werner, Schlossmacher, Michael, Schmahmann, Jeremy D, Tsuji, Shoji , Sutton, Sharon, Kaufmann, Horacio , Meissner, Wassilios G , Höglinger, Günter U , Krismer, Florian , Seppi, Klaus , Cummings, Jeffrey L. , Fortier, P, Freeman, Roy L. , LeWitt, Peter A. , Melki, Ronald , Poewe, Werner H , Robertson, David L. , Schmahmann, Jeremy Dan , Sutton, Sharon

Mayo Clinic

Neurology | December 13, 2017 | Volume: 90 | Issue: 2 | Pages: 74-82

10.1212/wnl.0000000000004798 | PMID 29237794 Get It

Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis
Lagares, David , Santos, Alba , Grasberger, Paula , Liu, Fei , Probst, Clemens K. , Rahimi, Rod A. , Sakai, Norihiko , Kuehl, Tobias, Ryan, Jeremy , Bhola, Patrick , Montero, Joan , Kapoor, Mohit , Varelas, Xaralabos , Tschumperlin, Daniel J. , Letai, Anthony , Tager, Andrew M. , Grasberger, Paula E , Baron, Murray , Tschumperlin, Daniel J , Lagares, David , Varelas, Xaralabos , Ryan, Jeremy

Mayo Clinic

Science Translational Medicine | December 13, 2017 | Volume: 9 | Issue: 420 | Pages: No page available

10.1126/scitranslmed.aal3765 | PMID 29237758 Get It

ABT-263 blocks BCL-X L to induce apoptosis in human dermal fibroblasts from patients with scleroderma and in myofibroblasts in mice, reversing dermal fibrosis.